A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
Completed
AstraZeneca
Phase 1
This is a phase I, randomised, single-blind, placebo-controlled, first-in-human (FIH) single
and multiple ascending dose study consisting of two parts (Part A [SAD] and Part B [MAD]) to
assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5718 in healthy
male subjects
A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718
Completed
AstraZeneca
Phase 1
This study is a randomized, open-label, 5-period, 5-treatment, single-dose, single-center,
crossover study to estimate the effect of AZD5718 on the pharmacokinetics (PK) of
rosuvastatin, and to assess the relative bioavailability of AZD5718 oral suspension vs
AZD5718 immediate release (IR) Tablet Formulation and the Food Effect of AZD5718 in Healthy
Volunteers. The study will be performed at a single study center.
AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).
Completed
AstraZeneca
Phase 2
This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in
patients with CAD. The study will be conducted at approximately 10 centres in 3 countries.
Approximately 138 CAD patients will be randomized to AZD5718 or placebo (treatment duration
12 weeks).
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men
Completed
AstraZeneca
Phase 1
This is a Phase I study to investigate the safety, tolerability, pharmacokinetics (PK) and
pharmacodynamics (PD) of the novel compound, AZD5718 in healthy Japanese men. The results
from this study will form the basis for decisions on future studies.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
